

PRESS RELEASE

For Immediate Release

Emergent Technologies, Inc. Hires Steven Lloyd Mayer, MD as Chief Medical Officer and Promotes Blake Harlan to Executive Vice President Finance and Operations

Austin, TX – February 13, 2019 – Emergent Technologies, Inc. (ETI) announced today that Steven Lloyd Mayer, MD has been hired as Chief Medical Officer to support commercialization efforts for its portfolio companies Pure MHC, LLC and Caisson Biotech, LLC and Blake Harlan will now serve as ETI's Executive Vice President Finance and Operations.

In his role as Chief Medical Officer, Dr. Mayer will be responsible for ongoing business development and strategic objectives at Pure MHC and Caisson Biotech. Dr. Mayer has over 25 years of diversified experience in diagnostics, medical devices and drug development. Since 2016, he has served as Chief Medical Officer for ETI portfolio company Pure Transplant Solutions, LLC. From 2002 to 2015, he was a Scientific Consultant and an Advisor to several healthcare companies including: Abbott Labs, GlucoSentient, Inc., RulesBasedMedicine, IAPAC, MeadWestVaco, Xhale Diagnostics, Psynova Neurotech Ltd., Organ Recovery Systems and HBM BioVentures.

From 1982 to 2002, Dr. Mayer held roles of increasing responsibility at Abbott; beginning as an engineer in Corporate Engineering and ultimately advancing to a Medical Director of Pharmacoeconomics and Outcomes Research and Associate Medical Director in Abbott's Pharmaceutical Products Division. Dr. Mayer has Doctor of Medicine and B.S. Chemical Engineering degrees, both from the University of Wisconsin - Madison.

In his new position as Executive Vice President Finance and Operations, Blake Harlan will be responsible for overseeing the alignment and execution of all financial and operational objectives for ETI, its Funds and Portfolio Companies. In addition, he will be leading the commercialization efforts of several portfolio companies including Caisson Biotech and Pure Transplant Solutions.

Since 2017, Mr. Harlan has served as Vice President Strategy and Operations where he drove strategic development for portfolio company's Pure MHC and Pure Transplant Solutions and was responsible for overseeing financial planning for ETI and its portfolio companies. He has experience across a wide variety of industries including antimicrobials, transplantation, plasma deposition, and immuno-oncology. Mr. Harlan holds a bachelor's degree in Economics from the University of Colorado at Boulder, and an MBA from the University of Texas at Austin.

About Emergent Technologies

Emergent Technologies, Inc. is an innovation solutions and technology commercialization leader headquartered in Austin, Texas. For more information visit www.etibio.com.

###

Media Contact:

Cameron Mackie

Email: cmackie@emergenttechnologies.com

Phone: (512) 697-8224